Resatorvid - Takeda

Drug Profile

Resatorvid - Takeda

Alternative Names: Compound(R)-(+)-5n; TAK 242; TAK-242 nanoparticle; TAK-242-NP

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Anti-inflammatories; Small molecules; Sulfonamides
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Septic shock

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 20 Feb 2009 Discontinued - Phase-III for Septic shock in Europe (SC)
  • 20 Feb 2009 Discontinued - Phase-III for Septic shock in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top